Watch: Biotech Going Up Against Big Pharma

As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “The goal is to get something to the market to help patients as soon as possible because they don’t have anything today,”

Follow us on social media for the latest updates in B2B!

Image

Latest

healthcare
From the C-Suite to the Classroom: A Healthcare Leader’s Bet on the Next Generation
May 25, 2026

Healthcare isn’t short on strategy right now—it’s short on people, access, and experienced leadership where it matters most. In Texas alone, more rural hospitals have closed than in any other state over the past decade, leaving entire communities with limited access to care. At the same time, many health systems are realizing they haven’t…

Read More
AI
The AI Health Score: Turning Hallucinations, Agents, and AI Risk Into Board-Ready Insight
May 24, 2026

As artificial intelligence moves deeper into enterprise operations, many organizations are discovering that the real challenge is not adoption, but control. Traditional software has always been predictable: the same input produces the same output, making it possible to audit systems at a fixed point in time. AI changes that equation. Jeff Carson, founder of…

Read More
TheAIAudit
Introducing TheAIAudit: A Platform Built to Measure, Monitor, and Govern Enterprise AI
May 22, 2026

Enterprise AI is advancing faster than most companies can govern it. Behind the scenes, AI systems are already influencing decisions tied to revenue, operations, compliance, customer outcomes, and risk — yet many organizations still lack a clear way to measure, explain, or oversee what those systems are doing. That is the gap TheAIAudit was…

Read More
Leadership
How the Future of Work Is Being Reshaped by AI, Human Creativity, and Customer-Centered Leadership
May 21, 2026

As artificial intelligence rapidly reshapes industries, many professionals are asking the same urgent question: what happens when AI starts replacing not just repetitive tasks, but the foundational entry-level roles that once launched careers? According to Goldman Sachs Research, AI could expose the equivalent of 300 million jobs globally to automation, while potentially automating tasks…

Read More